Ardana gets patent covering Teverelix

Teverelix is Ardana's lead development compound and is in phase II clinical trials for the treatment of both prostate cancer and benign prostatic hyperplasa. Ardana is also conducting phase I studies for the Teverelix treatment of endometriosis, a female condition characterised by tissue that normally lines the uterus growing outside of it, which condition can impair reproductive ability.